Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.09), GBP0.03 worse than the analyst estimate of (GBP0.06).

Outlook:-

Non-GAAP R&D expenses were $27.3 million for the second quarter of 2024, compared to $8.8 million for the same period of the prior year.

GAAP and Non-GAAP General and Administrative (G&A) Expenses

GAAP G&A expenses were $14.0 million for the second quarter of 2024, compared to $6.3 million for the same period of the prior year.

Non-GAAP G&A expenses were $6.4 million for the second quarter of 2024, compared to $5.2 million for the same period of the prior year.

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.